BIOMARKERS OF RESPONSE TO COMBINATION CABOZANTINIB + NIVOLUMAV IN ADVANCED RENAL CELL CARCINOMA

$671,250FY2022Department of the ArmyDOD

Brigham & Womens Hospital Inc

Investigators